Effect of Agave Inulin on Constipation and Quality of Life in Peritoneal Dialysis Patients.
brief summary
This is a randomized controlled clinical study realized in the nephrology service of the Centro Medico ISSEMyM hospital in Metepec, State of Mexico, including new patients on Peritoneal Dialysis (PD) over 18 years of age with constipation criteria, the Bristol scale and Rome IV Criteria were used, with a 6-month follow-up with a personalized diet plan, intervention group supplementation with agave Tequiliana blue variety inulin with an initial dose of 9 grams per day, the control gruop recived lactulosa. Data were obtained from the clinical history comorbidities present in the patients, anthropometric data such as weight, % of fat, % of body water, Fat Free Mass (FFM) obtained using a TANITA scale model BC-533; skin folds were obtained using a slim Guide plicometer, dietary data such as energy intake (kcal), protein intake, fluid intake, were estimated using a 24 hr reminder. A questionnaire was also applied to measure gastrointestinal symptoms and their evolution with the intervention, in addition to the KDQOL-SF to evaluate the quality of life of the patients.
detailed description
Constipation affects a large part of the population with Chronic Kidney Disease (CKD), and in Peritoneal Dialysis (PD) it is the most common symptom derived from multiple factors, including dietary restrictions causing insufficient fiber intake, water restriction, drug consumption and the change in the intestinal microbiota derived from uremic toxins during this stage, leading to a poor quality of life in the patient and consequently an alteration in the patient\'s nutritional status. In turn, constipation has become a risk factor in the development of cardiovascular diseases, of which patients with CKD have a higher incidence. This research aims to determine the effects of agave inulin supplementation on constipation and quality of life in peritoneal dialysis patients in order to establish a strategy to support patient treatment and improve uremic syndrome.
Lactulose syrup is usually used to prevent and treat constipation in doses from 10 ml every 8 hours.
The present research aims to determine the effects that agave inulin supplementation may have on constipation and quality of life in peritoneal dialysis patients, and to establish a strategy to support the patient\'s treatment and improve uremic syndrome.
Stage 1 Patients will be selected by the peritoneal dialysis team to identify the patients who start RRT, once identified, they will be referred to the nutrition office, where an initial evaluation of the patient will be made and if they meet the inclusion criteria, the informed consent will be explained and if they accept, they will be randomly assigned to the group they are assigned to. The laboratories requested to the patients are the same as those routinely requested by the treating physician. The characteristics of the nutritional intervention are detailed below. The characteristics of the first visit are detailed below.
Visit 1:
1. Evaluation of selection/inclusion criteria 2. Assessment in medical consultation 3. Signing of consent form. 4. Initial evaluation (File with: clinical, anthropometric, biochemical, dietary data). 5. Constipation evaluation with Bristol scale 6. Evaluation of quality of life with KDQOL-SF questionnaire. 7. Delivery of food plan and nutritional recommendations 8. Indication and delivery of the supplement according to the group. 9. Indicate that unfinished product should be returned. 10. Request for laboratory tests (routine tests that the nephrologist requests consultation after consultation). 11. Appointment every 30 days for delivery of supplement and adherence evaluation.
official title
Effect of Agave Inulin on Constipation and Quality of Life in Peritoneal Dialysis Patients